Labiotech.eu - Europe's leading Biotech News Website

The Top 10 Biotech Companies Brewing at Oxford

The Funding Flow Between European and US Life Sciences

Biotech Investment in Norway: An Alternative Approach

Latest News

Medical
17/09/2020
3D Bioprinting Gains a Foothold in Biomedicine
Cancer
16/09/2020
Cancer Research Heats up with Biotechs Attacking Tumor ‘Comfort Zone’
Cancer
14/09/2020
T-Cell Therapy Firm Wins Massive €93M Series A to Treat Solid Tumors
Industrial
10/09/2020
The Evolving Arsenal Against Mosquito-Borne Diseases
Food
08/09/2020
Investor Interest in Meat Alternative Biotechs Booms
Medical
03/09/2020
A Renaissance in Chronic Kidney Disease Treatment Is Underway
Microbiome
01/09/2020
Microbiome Therapies Threatened by Covid-19 Restrictions

Trending This Month

After Years of Neglect, Algae Biotechnology Makes a Comeback

A Renaissance in Chronic Kidney Disease Treatment Is Underway

A Renaissance in Chronic Kidney Disease Treatment Is Underway

Microbiome Therapies Threatened by Covid-19 Restrictions

Microbiome Therapies Threatened by Covid-19 Restrictions

Can Covid-19 Vaccines Keep up with an Evolving Virus?

Can Covid-19 Vaccines Keep up with an Evolving Virus?

This category can only be viewed by members. To view this category, sign up by purchasing Labiotech Insider Yearly Membership, Labiotech Insider Company Yearly Membership or Labiotech Insider Monthly Membership.

The Funding Flow Between European and US Life Sciences

Member Exclusive

This category can only be viewed by members. To view this category, sign up by purchasing Labiotech Insider Yearly Membership, Labiotech Insider Company Yearly Membership or Labiotech Insider Monthly Membership.

Negotiating Early-Stage Biotech Valuation: VC vs Entrepreneur

Member Exclusive

Why a US Presence Can Help European Biotechs Get Ahead

Member Exclusive

More Exclusive Content

Refresh Virtual: Immuno-oncology - The Investor's Perspective

Neutralizing a Threat: Sailors Spared from Coronavirus Reinfection

Sponsored by

PREP-ing for Future Pandemics and AMR

Sponsored by

Biotech Money Insider 2020 - Available Now For Insider Members

Content First: Labiotech’s Vision for 2020 and Beyond

Follow our Coverage of the Coronavirus